Zhibo Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zhibo Li has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Bin Liu
Department of Cardiology, The Second Hospital of Jilin University
1 shared publication - Guoliang Wang
Key Laboratory of Polymer Ecomaterials Changchun Institute of Applied Chemistry Chinese Academy of Sciences 5625 Renmin Street Changchun 130022 P. R. China
1 shared publication - Guoqing Wang
Jilin University
1 shared publication - Haochen Yao
Key Laboratory and Engineering Laboratory of Lymphatic Surgery Jilin Province, China-Japan Union Hospital, Jilin University, Changchun, 130033, China
1 shared publication - Jianxun Ding
Chinese Academy of Sciences
1 shared publication - Qiang Luo
Department of Cardiology, The Second Hospital of Jilin University, 4026 Yatai Street, Changchun, 130041, PR China
1 shared publication
Latest Publications
- 5 February 2025
- Published by Wiley in Advanced Materials
- Vol. 37 (11) , e2420171
Myocardia‐Injected Synergistically Anti‐Apoptotic and Anti‐Inflammatory Poly(amino acid) Hydrogel Relieves Ischemia‐Reperfusion Injury
Reperfusion therapy is the most effective treatment for acute myocardial infarction, but its efficacy is frequently limited by ischemia‐reperfusion injury (IRI). While antioxidant and anti‐inflammatory therapies have shown significant potential in alleviating IRI, these strategies have not yielded satisfactory clinical outcomes. For that, a thermo‐sensitive myocardial‐injectable poly(amino acid) hydrogel of methoxy poly(ethylene glycol)45‐poly(L‐methionine20‐co‐L‐alanine10) (mPEG45‐P(Met20‐co‐Ala10), PMA) loaded with FTY720 (PMA/FTY720) is developed to address IRI through synergistic anti‐apoptotic and anti‐inflammatory effects. Upon injection into the ischemic myocardium, the PMA aqueous solution undergoes a sol‐to‐gel phase transition and gradually degrades in response to reactive oxygen species (ROS), releasing FTY720 on demand. PMA acts synergistically with FTY720 to inhibit cardiomyocyte apoptosis and modulate pro‐inflammatory M1 macrophage polarization toward anti‐inflammatory M2 macrophages by clearing ROS, thereby mitigating the inflammatory response and promoting vascular regeneration. In a rat IRI model, PMA/FTY720 reduces the apoptotic cell ratio by 81.8%, increases vascular density by 34.0%, and enhances left ventricular ejection fraction (LVEF) by 12.8%. In a rabbit IRI model, the gel‐based sustained release of FTY720 enhanced LVEF by an additional 7.2% compared to individual treatment. In summary, the engineered PMA hydrogel effectively alleviates IRI through synergistic anti‐apoptosis and anti‐inflammation actions, offering valuable clinical potential for treating myocardial IRI.
- 5 February 2025
- Published by Wiley in Advanced Materials
- Vol. 37 (11) , e2420171
Myocardia‐Injected Synergistically Anti‐Apoptotic and Anti‐Inflammatory Poly(amino acid) Hydrogel Relieves Ischemia‐Reperfusion Injury
Reperfusion therapy is the most effective treatment for acute myocardial infarction, but its efficacy is frequently limited by ischemia‐reperfusion injury (IRI). While antioxidant and anti‐inflammatory therapies have shown significant potential in alleviating IRI, these strategies have not yielded satisfactory clinical outcomes. For that, a thermo‐sensitive myocardial‐injectable poly(amino acid) hydrogel of methoxy poly(ethylene glycol)45‐poly(L‐methionine20‐co‐L‐alanine10) (mPEG45‐P(Met20‐co‐Ala10), PMA) loaded with FTY720 (PMA/FTY720) is developed to address IRI through synergistic anti‐apoptotic and anti‐inflammatory effects. Upon injection into the ischemic myocardium, the PMA aqueous solution undergoes a sol‐to‐gel phase transition and gradually degrades in response to reactive oxygen species (ROS), releasing FTY720 on demand. PMA acts synergistically with FTY720 to inhibit cardiomyocyte apoptosis and modulate pro‐inflammatory M1 macrophage polarization toward anti‐inflammatory M2 macrophages by clearing ROS, thereby mitigating the inflammatory response and promoting vascular regeneration. In a rat IRI model, PMA/FTY720 reduces the apoptotic cell ratio by 81.8%, increases vascular density by 34.0%, and enhances left ventricular ejection fraction (LVEF) by 12.8%. In a rabbit IRI model, the gel‐based sustained release of FTY720 enhanced LVEF by an additional 7.2% compared to individual treatment. In summary, the engineered PMA hydrogel effectively alleviates IRI through synergistic anti‐apoptosis and anti‐inflammation actions, offering valuable clinical potential for treating myocardial IRI.